US Patent No: 6,749,868

Number of patents in Portfolio can not be more than 2000

Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof

1 Status Updates

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

In accordance with the present invention, there are provided compositions and methods useful for the in vivo delivery of substantially water insoluble pharmacologically active agents (such as the anticancer drug paclitaxel) in which the pharmacologically active agent is delivered in the form of suspended particles coated with protein (which acts as a stabilizing agent). In particular, protein and pharmacologically active agent in a biocompatible dispersing medium are subjected to high shear, in the absence of any conventional surfactants, and also in the absence of any polymeric core material for the particles. The procedure yields particles with a diameter of less than about 1 micron. The use of specific composition and preparation conditions (e.g., addition of a polar solvent to the organic phase), and careful election of the proper organic phase and phase fraction, enables the reproducible production of unusually small nanoparticles of less than 200 nm diameter, which can be sterile-filtered. The particulate system produced according to the invention can be converted into a redispersible dry powder comprising nanoparticles of water-insoluble drug coated with a protein, and free protein to which molecules of the pharmacological agent are bound. This results in a unique delivery system, in which part of the pharmacologically active agent is readily bioavailable (in the form of molecules bound to the protein), and part of the agent is present within particles without any polymeric matrix therein.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
ABRAXIS BIOSCIENCE, LLCLOS ANGELES, CA65

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Desai, Neil P Los Angeles, CA 194 7469
Louie, Leslie Montebello, CA 5 297
Magdassi, Shlomo Jerusalem, IL 58 759
Soon-Shiong, Patrick Los Angeles, CA 205 4662
Tao, Chunlin Beverly Hills, CA 57 657
Yang, Andrew Rosemead, CA 33 938
Yao, Zhiwen Culver City, CA 4 301

Cited Art Landscape

Patent Info (Count) # Cites Year
 
GENSIA SICOR PHARMACEUTICALS, INC. (1)
6,469,069 Propofol composition containing sulfite 25 2000
 
NOVARTIS CORPORATION (1)
5,744,460 Combination for treatment of proliferative diseases 37 1996
 
AMERICAN HOME PRODUCTS CORPORATION (1)
4,344,934 Therapeutic compositions with enhanced bioavailability 49 1980
 
BRISTOL-MYERS SQUIBB COMPANY (1)
5,504,102 Stabilized pharmaceutical composition and stabilizing solvent 58 1995
 
GENSIA SICOR INC. (1)
6,147,122 Propofol composition containing sulfite 27 1999
 
TEKMIRA PHARMACEUTICALS CORPORATION (1)
5,543,152 Sphingosomes for enhanced drug delivery 99 1994
 
VETERINARY RESEARCH ASSOCIATES, INC. (1)
5,962,536 Injectable propofol formulations 20 1998
 
CEPHALON LIMITED (1)
5,683,715 Taxane-containing phosphatidylcholine liposomes 31 1995
 
GEORGETOWN UNIVERSITY (1)
5,648,090 Liposome encapsulated toxol and a method of using the same 24 1995
 
NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT (1)
5,565,478 Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs 45 1994
 
Research Triangle Pharmaceuticals (1)
5,637,625 Propofol microdroplet formulations 48 1996
 
The Scripps Research Institute (1)
5,731,334 Method for treating cancer using taxoid onium salt prodrugs 7 1995
 
Vyrex Corporation (1)
6,362,234 Water-soluble prodrugs of propofol for treatment of migrane 27 2000
 
MASSACHUSETTS INSTITUTE OF TECHNOLOGY (1)
5,626,862 Controlled local delivery of chemotherapeutic agents for treating solid tumors 219 1994
 
Westy AG (1)
6,326,406 Clear, injectable formulation of an anesthetic compound 23 2000
 
HOSPIRA, INC. (1)
6,140,373 Propofol composition 25 1998
 
BAXTER INTERNATIONAL INC. (1)
6,100,302 Propofol formulation with enhanced microbial characteristics 29 1999
 
PG-TXL Company, L.P. (1)
5,977,163 Water soluble paclitaxel prodrugs 236 1997
 
ELAN PHARMA INTERNATIONAL LIMITED (1)
5,399,363 Surface modified anticancer nanoparticles 248 1992
 
FAULDING PHARMACEUTICAL CO. (2)
6,028,108 Propofol composition comprising pentetate 30 1998
6,177,477 Propofol formulation containing TRIS 27 1999
 
ABRAXIS BIOSCIENCE, LLC (5)
5,439,686 Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor 203 1993
5,498,421 Composition useful for in vivo delivery of biologics and methods employing same 278 1994
* 5,916,596 Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof 165 1996
6,096,331 Methods and compositions useful for administration of chemotherapeutic agents 125 1997
* 6,537,579 Compositions and methods for administration of pharmacologically active compounds 107 2000
 
AMPHASTAR PHARMACEUTICALS, INC. (1)
6,399,087 Propofol formulation with enhanced microbial inhibition 22 2000
 
IVX ANIMAL HEALTH, INC. (1)
6,150,423 Propofol-based anesthetic and method of making same 26 1998
 
ZENECA LIMITED (4)
5,714,520 Propofol compostion containing edetate 54 1995
5,731,355 Pharmaceutical compositions of propofol and edetate 56 1997
5,731,356 Pharmaceutical compositions of propofol and edetate 35 1997
5,908,869 Propofol compositions containing edetate 31 1998
* Cited By Examiner

Patent Citation Ranking

Forward Cite Landscape

Patent Info (Count) # Cites Year
 
Other [Check patent profile for assignment information] (2)
* 6,995,145 Methods and compositions for modulating drug activity through telomere damage 3 2000
* 8,449,919 Composition and method for preparing alginate nanocapsules 0 2006
 
INTERHEALTH NUTRACEUTICALS INCORPORATED (2)
8,748,499 Collagen dispersion and method of producing same 0 2010
* 2010/0303,898 COLLAGEN DISPERSION AND METHOD OF PRODUCING SAME 1 2010
 
NITTO DENKO CORPORATION (7)
* 2007/0128,118 POLYGLUTAMATE-AMINO ACID CONJUGATES AND METHODS 35 2006
* 2008/0181,852 Multi-functional Drug Carriers 4 2008
* 2008/0253,969 MULTI-FUNCTIONAL POLYGLUTAMATE DRUG CARRIERS 7 2008
8,197,828 Compositions that include a hydrophobic compound and a polyamino acid conjugate 0 2008
* 2008/0279,782 POLYMERS CONJUGATED WITH PLATINUM DRUGS 5 2008
* 2009/0226,393 POLYMER PACLITAXEL CONJUGATES AND METHODS FOR TREATING CANCER 5 2009
8,329,199 Compositions that include a hydrophobic compound and a polyamino acid conjugate 0 2012
 
SALPIETRA, JOHN M. "PETE",ROCHESTER HILLS,MI, SALPIETRA JOSEPH ANTHONY JR,"SALPIETRA, JOSEPH ANTHONY, JR. (2)
* 8,273,560 Coated substrates and methods of preparing the same 0 2011
* 2012/0028,328 COATED SUBSTRATES AND METHODS OF PREPARING THE SAME 0 2011
 
Nanjing Effect Pharm Drug Development Corporation (2)
* 9,066,870 Methods for drug delivery comprising unfolding and folding proteins and peptide nanoparticles 0 2010
* 2011/0059,181 METHODS FOR DRUG DELIVERY COMPRISING UNFOLDING AND FOLDING PROTEINS AND PEPTIDE NANOPARTICLES 0 2010
 
UNIVERSITY OF NORTH TEXAS (2)
8,048,450 Aqueous dispersion of hydrogel nanoparticles with inverse thermoreversible gelation 0 2004
* 2007/0116,765 Aqueous dispersion of hydrogel nanoparticles with inverse thermoreversible gelation 3 2004
 
LUMINUS BIOSCIENCES, INC. (2)
8,728,527 Solid nanoparticle formulation of water insoluble pharmaceutical substances with reduced ostwald ripening 25 2007
* 2009/0238,878 Solid Nanoparticle Formulation of Water Insoluble Pharmaceutical Substances With Reduced Ostwald Ripening 5 2007
 
MASSACHUSETTS INSTITUTE OF TECHNOLOGY (1)
* 2009/0074,828 POLY(AMINO ACID) TARGETING MOIETIES 62 2008
 
MINU, L.L.C. (1)
* 2005/0181,018 Ocular drug delivery 26 2005
 
PEYMAN, GHOLAM A. (5)
7,722,581 Crystalline lens drug delivery 4 2005
* 2006/0225,745 Crystalline lens drug delivery 0 2005
* 2006/0229,585 DRUG DELIVERY TO THE CRYSTALLINE LENS AND OTHER OCULAR STRUCTURES 2 2006
7,458,953 Ocular drainage device 23 2006
* 2007/0293,872 Ocular Drainage Device 26 2006
 
BEIJING HONGYIYAO SCIENCE & TECHNOLOGY DEVELOPMENT CO. LTD. (1)
* 2008/0020,052 Vascular Embolus Of Paclitaxel-Sodium Alginate Microsphere And Its Preparation 2 2005
 
Celgene Corporation (1)
9,125,884 Methods for treating cancers using oral formulations of cytidine analogs 0 2012
 
ELAN PHARMA INTERNATIONAL LIMITED (5)
* 2003/0054,042 Stabilization of chemical compounds using nanoparticulate formulations 27 2001
* 2004/0033,267 Nanoparticulate compositions of angiogenesis inhibitors 16 2003
* 2006/0210,638 Injectable compositions of nanoparticulate immunosuppressive compounds 29 2006
* 2006/0292,214 Nanoparticulate acetaminophen formulations 15 2006
* 2008/0226,732 NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS 0 2007
 
BIOMED REALTY, L.P. (6)
7,964,196 Self-assembling nanoparticle drug delivery system 5 2005
* 2006/0292,174 Self-assembling nanoparticle drug delivery system 12 2005
8,067,011 Compositions and methods for treating B-cell malignancies 2 2007
* 2007/0269,370 Compositions and methods for treating B-cell malignancies 6 2007
9,017,695 Chimeric therapeutics, compositions, and methods for using same 0 2011
8,865,188 Methods and compositions for controlling assembly of viral proteins 0 2012
 
ALKERMES PHARMA IRELAND LIMITED (1)
* 2009/0004,277 Nanoparticle dispersion containing lactam compound 3 2005
 
AMERICAN BIOSCIENCE, INC. (1)
8,846,771 Compositions and methods of delivery of pharmacological agents 9 2012
 
FRESENIUS KABI USA, LLC (3)
8,889,346 Propofol formulations with non-reactive container closures 0 2013
9,072,655 Propofol formulations with non-reactive container closures 0 2014
9,072,656 Propofol formulations with non-reactive container closures 0 2014
 
ASTRAZENECA AB (1)
9,402,847 Combinations comprising (S)-4-amino-N-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide 0 2012
 
LIQUIDIA TECHNOLOGIES, INC. (1)
* 2010/0055,459 Nanoparticles Having Functional Additives for Self and Directed Assembly and Methods of Fabricating Same 4 2007
 
MERCATOR MEDSYSTEMS, INC. (1)
9,061,014 Intravascular delivery of nanoparticle compositions and uses thereof 4 2012
 
CHEVRON PHILLIPS CHEMICAL COMPANY LP (1)
8,809,562 Use of metallocene compounds for cancer treatment 0 2012
 
SYNTA PHARMACEUTICALS CORP. (16)
7,763,658 Treatment for cancers 10 2004
* 2004/0225,016 Treatment for cancers 18 2004
8,017,654 Combination cancer therapy with bis(thiohydrazide) amide compounds 1 2006
* 2009/0137,682 Combination cancer therapy with bis(thiohydrazide) amide compounds 20 2006
7,939,564 Combination with bis(thiohydrazide amides) for treating cancer 2 2007
7,671,092 Paclitaxel enhancer compounds 11 2008
7,750,042 Paclitaxel enhancer compound 10 2008
7,652,168 Synthesis of taxol enhancers 10 2008
* 2009/0005,594 Synthesis of taxol enhancers 14 2008
7,795,313 Bis(thio-hydrazide amide) salts for treatment of cancers 13 2009
* 2009/0281,172 BIS(THIO-HYDRAZIDE AMIDE) SALTS FOR TREATMENT OF CANCERS 3 2009
9,107,955 Paclitaxel enhancer compounds 0 2010
8,048,925 Bis(thio-hydrazide amide) salts for treatment of cancers 3 2010
* 2010/0324,143 BIS(THIO-HYDRAZIDE AMIDE) SALTS FOR TREATMENT OF CANCERS 11 2010
8,461,208 Bis(thio-hydrazide amide) salts for treatment of cancers 2 2011
9,156,783 Compounds for treating proliferative disorders 0 2013
 
TEIKOKU PHARMA USA, INC. (3)
8,569,357 Taxane pro-emulsion formulations and methods making and using the same 0 2011
8,940,786 Non-aqueous taxane nanodispersion formulations and methods of using the same 1 2013
9,308,195 Non-aqueous taxane formulations and methods of using the same 0 2014
 
DUKE UNIVERSITY (2)
8,013,022 Stabilized products, process and devices for preparing same 0 2007
* 2007/0258,960 Stabilized products, process and devices for preparing same 3 2007
 
ONCBIOMUNE, INC. (2)
9,333,189 Taxane- and taxoid-protein compositions 0 2011
* 2011/0190,204 Taxane- and Taxoid-Protein Compositions 1 2011
 
CERULEAN PHARMA INC. (6)
8,497,365 Cyclodextrin-based polymers for therapeutics delivery 0 2011
8,404,662 Cyclodextrin-based polymers for therapeutics delivery 0 2012
8,609,081 Cyclodextrin-based polymers for therapeutics delivery 0 2013
8,580,242 Cyclodextrin-based polymers for therapeutics delivery 0 2013
8,518,388 Cyclodextrin-based polymers for therapeutics delivery 0 2013
8,603,454 Cyclodextrin-based polymers for therapeutics delivery 0 2013
 
ABRAXIS BIOSCIENCE, INC. (3)
* 2007/0122,465 Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof 5 2006
* 2007/0191,473 Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof 2 2006
* 2007/0122,468 Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof 5 2006
 
ABRAXIS BIOSCIENCE, LLC (49)
* 2003/0199,425 Compositions and methods for treatment of hyperplasia 29 2001
* 2005/0004,002 Compositions and methods of delivery of pharmacological agents 42 2003
8,034,375 Combinations and modes of administration of therapeutic agents and combination therapy 16 2006
* 2006/0263,434 Combinations and modes of administration of therapeutic agents and combination therapy 35 2006
8,034,765 Compositions and methods for preparation of poorly water soluble drugs with increased stability 42 2006
7,771,751 Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents 19 2006
* 2007/0117,744 Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents 22 2006
* 2007/0082,838 Compositions and methods for preparation of poorly water soluble drugs with increased stability 42 2006
8,853,260 Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof 9 2006
8,137,684 Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof 16 2006
* 2007/0092,563 Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof 14 2006
* 2007/0093,547 Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof 28 2006
8,257,733 Methods and compositions for treating proliferative diseases 17 2006
* 2007/0116,774 Methods and compositions for treating proliferative diseases 26 2006
7,820,788 Compositions and methods of delivery of pharmacological agents 21 2006
* 2010/0226,996 COMPOSITIONS AND METHODS OF DELIVERY OF PHARMACOLOGICAL AGENTS 6 2006
* 2007/0129,448 COMPOSITIONS AND METHODS OF DELIVERY OF PHARMACOLOGICAL AGENTS 27 2006
* 2007/0128,290 Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof 11 2006
* 7,780,984 Methods and compositions for treating proliferative diseases 14 2007
* 2008/0063,724 Methods and compostions for treating proliferative diseases 15 2007
* 2008/0280,987 Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases 23 2007
* 2010/0048,499 BREAST CANCER THERAPY BASED ON HORMONE RECEPTOR STATUS WITH NANOPARTICLES COMPRISING TAXANE 24 2007
8,911,786 Nanoparticle comprising rapamycin and albumin as anticancer agent 7 2008
8,927,019 Methods and compositions for treating recurrent cancer 7 2008
* 2010/0215,751 METHODS AND COMPOSITIONS FOR TREATING RECURRENT CANCER 22 2008
7,758,891 Combinations and modes of administration of therapeutic agents and combination therapy 17 2008
* 2009/0098,210 COMBINATIONS AND MODES OF ADMINISTRATION OF THERAPEUTIC AGENTS AND COMBINATION THERAPY 16 2008
7,981,445 Compositions and methods for preparation of poorly water soluble drugs with increased stability 16 2009
* 2009/0196,933 COMPOSITIONS AND METHODS FOR PREPARATION OF POORLY WATER SOLUBLE DRUGS WITH INCREASED STABILITY 19 2009
* 2009/0263,483 NANOPARTICLE FORMULATIONS AND USES THEREOF 25 2009
8,735,394 Combinations and modes of administration of therapeutic agents and combination therapy 11 2009
* 2009/0304,805 COMBINATIONS AND MODES OF ADMINISTRATION OF THERAPEUTIC AGENTS AND COMBINATION THERAPY 22 2009
7,923,536 Compositions and methods of delivery of pharmacological agents 19 2010
* 2011/0118,342 COMPOSITIONS AND METHODS FOR PREPARATION OF POORLY WATER SOLUBLE DRUGS WITH INCREASED STABILITY 18 2010
* 2011/0151,012 COMPOSITIONS COMPRISING POORLY WATER SOLUBLE PHARMACEUTICAL AGENTS AND ANTIMICROBIAL AGENTS 18 2010
* 2011/0165,256 COMPOSITIONS AND METHODS FOR TREATMENT OF HYPERPLASIA 14 2010
8,138,229 Compositions and methods of delivery of pharmacological agents 18 2010
8,314,156 Compositions and methods of delivery of pharmacological agents 18 2011
9,370,494 Methods for treating hepatocellular carcinoma 0 2011
9,393,318 Methods of treating cancer 0 2011
9,399,071 Methods of treatment of pancreatic cancer 0 2011
8,268,348 Combinations and modes of administration of therapeutic agents and combination therapy 18 2011
9,308,180 Compositions and methods for preparation of poorly water soluble drugs with increased stability 0 2012
9,101,543 Combinations and modes of administration of therapeutic agents and combination therapy 5 2012
9,012,518 Compositions and methods of delivery of pharmacological agents 5 2013
9,012,519 Compositions and methods of delivery of pharmacological agents 5 2013
8,999,396 Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane 7 2013
9,399,072 Methods of treatment of pancreatic cancer 0 2013
9,149,455 Methods of treating melanoma 4 2013
* Cited By Examiner